Literature DB >> 1087551

Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients.

B Vernon-Roberts, J L Doré, J D Jessop, W J Henderson.   

Abstract

Gold distribution was studied in the tissues of 7 rheumatoid patients who had died from 0 to 23 years after stopping chrysotherapy (sodium aurothiomalate) and in 23 samples of synovial tissue removed surgically at intervals during chrysotherapy in 5 patients. After the application of a highly specific staining technique, the cellular localization of gold was examined microscopically in various tissues: the amounts of gold in selected areas of the same specimens which had been examined microscopically were then measured by neutron activation analysis. During active chrysotherapy gold was abundant in synovial lining cells except where a fibrin layer was present on the surface; after stopping chrysotherapy, gold disappeared from the synovial lining cells. Gold accumulated progressively in the subsynovial connective tissues during chrysotherapy, but was not uniformly distributed, and bore no relationship to fluctuations in serum gold levels. Gold deposition was not confined to joint tissue, but was found within the macrophages of many organs, renal tubular epithelium, and, after recent chrysotherapy, in seminiferous tubules, hepatocytes, and adrenal cortical cells. Gold persisted in synovial and other tissues for up to 23 years after chrysotherapy was stopped. The overall findings indicated that gold is selectively concentrated within inflamed synovial tissues during chrysotherapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1087551      PMCID: PMC1006590          DOI: 10.1136/ard.35.6.477

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

1.  HEBERDEN ORATION, 1964. SOME IMMUNOLOGIC ASPECTS OF THE CONNECTIVE TISSUE DISEASES.

Authors:  M ZIFF
Journal:  Ann Rheum Dis       Date:  1965-03       Impact factor: 19.103

2.  A method for the selective demonstration of gold in tissue sections.

Authors:  J L Doré; B Vernon-Roberts
Journal:  Med Lab Sci       Date:  1976-07

3.  Effects of gold salts and prednisolone on inflammatory cells. I. Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a "skin-window" technique in rheumatoid and control patients.

Authors:  J D Jessop; B Vernon-Roberts; J Harris
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

4.  Proceedings: Extracellular release of cathepsin D from cells in human normal and rheumatoid.

Authors:  A R Poole; R M Hembry; J T Dingle; I Pinder; E F Ring; J Cosh
Journal:  Ann Rheum Dis       Date:  1974-07       Impact factor: 19.103

5.  Tissue gold levels after chrysotherapy.

Authors:  R Grahame; R Billings; M Laurence; V Marks; P J Wood
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

Review 6.  The granulomatous inflammatory exudate.

Authors:  W G Spector
Journal:  Int Rev Exp Pathol       Date:  1969

7.  Electron-dense deposits following injection of gold sodium thiomalate and thiomalic acid.

Authors:  W L Norton; D C Lewis; M Ziff
Journal:  Arthritis Rheum       Date:  1968-06

8.  Gold nephropathy. A clinical and pathologic study.

Authors:  D S Silverberg; E G Kidd; T K Shnitka; R A Ulan
Journal:  Arthritis Rheum       Date:  1970 Nov-Dec

9.  Kinetics of aurothiomalate in serum and synovial fluid.

Authors:  R C Gerber; H E Paulus; R Bluestone; M Lederer
Journal:  Arthritis Rheum       Date:  1972 Nov-Dec

10.  The effect of gold salt on lysosomal enzymes of the peritoneal macrophage.

Authors:  R H Persellin; M Ziff
Journal:  Arthritis Rheum       Date:  1966-02
View more
  22 in total

1.  Professor Barrie Vernon-Roberts, AO, MD, BSc, PhD, FRCPath, FRCPA, FAOrthA (Hon), FRS.SA.

Authors:  K D Rainsford; D R Haynes
Journal:  Inflammopharmacology       Date:  2013-07-04       Impact factor: 4.473

Review 2.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

3.  Effect of gold salt treatment on the receptor binding activity of monocytes and macrophages isolated from rats with adjuvant arthritis.

Authors:  D R Haynes; I R Garrett; B Vernon-Roberts
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

4.  The anti-inflammatory profile of dapsone in animal models of inflammation.

Authors:  A J Lewis; D K Gemmell; W H Stimson
Journal:  Agents Actions       Date:  1978-12

5.  Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.

Authors:  M L Handel; C K Watts; A deFazio; R O Day; R L Sutherland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST).

Authors:  D E Furst; S H Dromgoole
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

7.  Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis.

Authors:  B D Williams; M M O'Sullivan; G S Saggu; K E Williams; L A Williams; J R Morgan
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

8.  A comparison of the effects of two gold-containing therapeutic agents on articular chondrocyte growth in vitro.

Authors:  C J Kirkpatrick; W Mohr
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

Review 9.  Conditional pharmacology/toxicology V: ambivalent effects of thiocyanate upon the development and the inhibition of experimental arthritis in rats by aurothiomalate (Myocrysin®) and metallic silver.

Authors:  Michael Whitehouse; Desley Butters; Barrie Vernon-Roberts
Journal:  Inflammopharmacology       Date:  2013-05-19       Impact factor: 4.473

10.  Sodium aurothiomalate does not block interleukin 1 production in rabbits.

Authors:  Y Zurovsky; H P Laburn; D Mitchell; A Ruck
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.